The African Centre for Biodiversity (ACB) welcomes you to our website. We are a research and advocacy organisation working towards food sovereignty and agro-ecology in Africa, with a focus on biosafety, seed systems and agricultural biodiversity. The organisation is committed to dismantling inequalities and resisting corporate-industrial expansion in Africa's food and agriculture systems.
A review of some outstanding issues in the negotiation
Will the effort to fix ITPGRFA’s broken benefit sharing system measure up to expectations?
This paper reviews the key outstanding issues that are expected to be discussed by the ITPGRFA Governing Body, and makes recommendations for what developing countries, farmers, and other civil society should support in November’s decisive negotiation.
Resounding no to Monsanto’s ‘bogus’ GM drought tolerant maize: South Africa’s Minister, Appeal Board and Biosafety Authority Reject Monsanto’s GM seeds
Johannesburg, South Africa, 4 October 2019
After more than 10 years of battling Monsanto’s ‘bogus’ drought tolerant maize project, the African Centre for Biodiversity (ACB) welcomes the decision by the Minister of Agriculture, Ms. Thoko Didiza, upholding of both the decision by the Executive Council: GMO Act and the Appeal Board to reject Monsanto’s application for the commercial cultivation of its triple stacked ‘drought-tolerant’ GM maize seed.
Civil society organisations and citizens across Africa are calling upon their governments to issue an immediate ban on all use of glyphosate and glyphosate-based herbicides (GBHs).
Launched by the Alliance for Food Sovereignty in Africa (AFSA) and the African Centre for Biodiversity (ACB), the #BanGlyphosateAfrica campaign has been endorsed by African organisations representing millions of African citizens. Governments across the continent are being inundated with messages, letters and petitions demanding that they protect their citizens with an immediate ban.
Globally, glyphosate and GBHs have contaminated all spheres of our environment and food systems, kicking off one of the world’s biggest health crises. Chronic diseases have increased in tandem with GBH use globally, as recent court cases in the USA have shown.